These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 23650219)

  • 1. Treatment with topotecan plus cyclophosphamide in children with first relapse of neuroblastoma.
    Ashraf K; Shaikh F; Gibson P; Baruchel S; Irwin MS
    Pediatr Blood Cancer; 2013 Oct; 60(10):1636-41. PubMed ID: 23650219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study.
    London WB; Frantz CN; Campbell LA; Seeger RC; Brumback BA; Cohn SL; Matthay KK; Castleberry RP; Diller L
    J Clin Oncol; 2010 Aug; 28(24):3808-15. PubMed ID: 20660830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.
    Hunold A; Weddeling N; Paulussen M; Ranft A; Liebscher C; Jürgens H
    Pediatr Blood Cancer; 2006 Nov; 47(6):795-800. PubMed ID: 16411206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclophosphamide and topotecan as first-line salvage therapy in patients with relapsed ewing sarcoma at a single institution.
    Farhat R; Raad R; Khoury NJ; Feghaly J; Eid T; Muwakkit S; Abboud M; El-Solh H; Saab R
    J Pediatr Hematol Oncol; 2013 Jul; 35(5):356-60. PubMed ID: 23042020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serial intense chemotherapy combining topotecan, etoposide, carboplatin and cyclophosphamide (TECC) followed by autologous hematopoietic stem cell support in patients with high risk soft tissue sarcoma (STS).
    Bernbeck B; Bahci S; Meisel R; Troeger A; Schönberger S; Laws HJ; Kramm C; Wessalowski R; Koscielniak E; Dilloo D; Göbel U
    Klin Padiatr; 2007; 219(6):318-22. PubMed ID: 18050041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of relapsed Wilms' tumor with high-dose therapy and autologous hematopoietic stem-cell rescue: the experience at Children's Memorial Hospital.
    Campbell AD; Cohn SL; Reynolds M; Seshadri R; Morgan E; Geissler G; Rademaker A; Marymount M; Kalapurakal J; Haut PR; Duerst R; Kletzel M
    J Clin Oncol; 2004 Jul; 22(14):2885-90. PubMed ID: 15254057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma?
    Al-Faris N; Al Harbi T; Goia C; Pappo A; Doyle J; Gassas A
    Pediatr Blood Cancer; 2007 Aug; 49(2):190-5. PubMed ID: 17262797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update.
    George RE; Li S; Medeiros-Nancarrow C; Neuberg D; Marcus K; Shamberger RC; Pulsipher M; Grupp SA; Diller L
    J Clin Oncol; 2006 Jun; 24(18):2891-6. PubMed ID: 16782928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topotecan, thiotepa, and carboplatin for neuroblastoma: failure to prevent relapse in the central nervous system.
    Kushner BH; Kramer K; Modak S; Kernan NA; Reich LM; Danis K; Cheung NK
    Bone Marrow Transplant; 2006 Feb; 37(3):271-6. PubMed ID: 16400336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: pharmacological rationale and clinical response.
    Donfrancesco A; De Ioris MA; McDowell HP; De Pasquale MD; Ilari I; Jenkner A; Castellano A; Cialfi S; De Laurentis C; Dominici C
    Pediatr Blood Cancer; 2010 Jan; 54(1):55-61. PubMed ID: 19821523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults.
    Kushner BH; Cheung NK; Kramer K; Dunkel IJ; Calleja E; Boulad F
    Bone Marrow Transplant; 2001 Sep; 28(6):551-6. PubMed ID: 11607767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study.
    Kretschmar CS; Kletzel M; Murray K; Thorner P; Joshi V; Marcus R; Smith EI; London WB; Castleberry R
    J Clin Oncol; 2004 Oct; 22(20):4119-26. PubMed ID: 15483021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk neuroblastoma patients.
    Molina B; Alonso L; Gonzalez-Vicent M; Andion M; Hernandez C; Lassaletta A; Cormenzana M; Lopez-Ibor B; Villa M; Molina J; Diaz MA
    Pediatr Hematol Oncol; 2011 Mar; 28(2):115-23. PubMed ID: 21299340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study.
    Di Giannatale A; Dias-Gastellier N; Devos A; Mc Hugh K; Boubaker A; Courbon F; Verschuur A; Ducassoul S; Malekzadeh K; Casanova M; Amoroso L; Chastagner P; Zwaan CM; Munzer C; Aerts I; Landman-Parker J; Riccardi R; Le Deley MC; Geoerger B; Rubie H
    Eur J Cancer; 2014 Jan; 50(1):170-7. PubMed ID: 24021349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
    Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
    Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloablative chemotherapy with autologous peripheral blood stem cell transplantation in patients with poor-prognosis solid tumors - Bulgarian experience.
    Avramova B; Jordanova M; Michailov G; Konstantinov D; Christosova I; Bobev D
    J BUON; 2006; 11(4):433-8. PubMed ID: 17309174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer.
    Donato ML; Gershenson DM; Wharton JT; Ippoliti CM; Aleman AS; Bodurka-Bevers D; Bevers MW; Burke TW; Levenback CF; Wolf JK; Freedman RS; Bast RC; Gajewski JL; Champlin RE
    Gynecol Oncol; 2001 Sep; 82(3):420-6. PubMed ID: 11520135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topotecan plus cyclophosphamide as maintenance chemotherapy for children with high-risk neuroblastoma in complete remission: short-term curative effects and toxicity.
    Feng C; Tang S; Wang J; Liu Y; Yang G
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Aug; 33(8):1107-10. PubMed ID: 23996746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A modified protocol with vincristine, topotecan, and cyclophosphamide for recurrent/progressive ewing sarcoma family tumors.
    Kebudi R; Cakir FB; Gorgun O; Agaoglu FY; Darendeliler E
    Pediatr Hematol Oncol; 2013 Apr; 30(3):170-7. PubMed ID: 23484903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.